rs30021 — SNX24 VEGFA Vascular Growth Co-variant

SNX24 and Vascular Homeostasis — The Sorting Nexin That Guards Your Vessel Walls

Inside every vascular endothelial cell and platelet-producing megakaryocyte, a molecular sorting system routes proteins to exactly where they need to go. SNX24 — sorting nexin 24¹¹ SNX24 — sorting nexin 24
a member of the PX-domain sorting nexin family; binds phosphoinositide lipids on endosomal membranes and guides cargo vesicles through the intracellular trafficking network — is one component of this system, specifically required for building platelet alpha-granules and regulating endothelial cytokine output. The rs30021 variant lies deep within the SNX24 gene (c.249+4040G>A), in a non-coding intron region that may influence how much SNX24 is produced in vascular tissues.

While rs30021 itself has not been the direct subject of a published clinical trial, it sits in a biologically rich locus. SNX24's documented roles — controlling von Willebrand factor (VWF) release from platelets and modulating the endothelial inflammatory response — are directly relevant to cardiovascular and venous disease. The G allele of rs30021 is uncommon globally (~23% allele frequency), with marked variation across ancestries: European populations carry it at ~31%, East Asian populations at just ~1%.

The Mechanism

SNX24 acts in the alpha-granule maturation pathway²² alpha-granule maturation pathway
alpha-granules are the most abundant organelle in platelets, storing key hemostatic proteins including VWF, P-selectin, fibrinogen, and platelet factor 4 of megakaryocytes — the bone marrow precursor cells that produce platelets. When SNX24 is knocked out experimentally, megakaryocytes accumulate empty membrane vesicles, fail to form mature multivesicular bodies, and produce platelets that are severely depleted in alpha-granule cargo including VWF and CD62P (P-selectin). These proteins are critical for the initial steps of hemostasis and thrombus formation at sites of vascular injury.

In endothelial cells, SNX24 plays a second, independent role: modulating the inflammatory cytokine response to bacterial lipopolysaccharide. When SNX24 expression is suppressed, endothelial cells produce significantly less IL-1β, IL-6, and IL-8 in response to inflammatory signals. This positions SNX24 as a regulator of endothelial activation — the cellular process that initiates leukocyte recruitment, promotes coagulation, and drives the vascular inflammatory response underlying atherosclerosis and venous wall remodeling.

The rs30021 intronic variant (c.249+4040G>A) does not change the SNX24 protein sequence directly. Deeply intronic variants can influence gene expression through effects on splicing enhancers, intronic regulatory elements, or chromatin accessibility. Whether rs30021 affects SNX24 expression in endothelial or megakaryocyte lineages has not been characterized experimentally.

The Evidence

The direct evidence for rs30021 is limited: no published GWAS hit, no ClinVar entry, and no primary study investigating its phenotypic consequence. It appears in the related-variant set of the VEGFA/5q region varicose vein GWAS context, identified in Ahmed et al. 2022³³ Ahmed et al. 2022
two-stage analysis across 810,000 participants identifying 49 genome-wide significant varicose vein loci.

The biological evidence for SNX24's vascular role is stronger. Lacey et al. 2022⁴⁴ Lacey et al. 2022
CRISPR-Cas9 knockout in iPSC-derived megakaryocytes; n=3 cell lines per condition demonstrated that SNX24 loss eliminates alpha-granule maturation, with direct measurement of VWF reduction — a key coagulation factor also implicated in venous thromboembolism. A separate genetic study Lin et al. 2013⁵⁵ Lin et al. 2013
262 Kawasaki disease patients, 76 with coronary artery aneurysm showed that SNX24 variant rs28891 (a different coding variant in the same gene) associates with coronary artery aneurysm severity, and that endothelial cells with reduced SNX24 expression produce less IL-1β, IL-6, and IL-8 — directly connecting SNX24 function to vascular inflammation.

Given the indirect nature of evidence for rs30021 specifically, this SNP is rated emerging. The classification may be upgraded if eQTL studies confirm that rs30021-G reduces SNX24 expression in vascular or platelet precursor tissues.

Practical Actions

For G allele carriers, the theoretical concern is reduced SNX24 expression in two cell types: megakaryocytes (platelets) and endothelial cells. Reduced SNX24 in megakaryocytes could impair alpha-granule loading, affecting VWF release and platelet adhesion capacity at vascular injury sites. Reduced SNX24 in endothelium could reduce inflammatory cytokine output — a potentially protective effect that makes the directionality of this variant complex.

Monitoring VWF levels (including VWF antigen and activity) can capture downstream effects of platelet alpha-granule dysfunction. VWF Ag below 50% is defined as von Willebrand disease type 1, though this is generally driven by VWF gene variants; moderately low VWF activity (50–100%) influences both bleeding tendency and, paradoxically, cardiovascular risk stratification.

Interactions

rs30021 is listed as a co-variant alongside rs11967262 — a VEGFA upstream regulatory variant strongly associated with varicose veins through the 6p21.1 locus. The co-listing reflects their co-occurrence in varicose vein genetic research rather than physical LD (they are on different chromosomes: rs30021 on chr5, rs11967262 on chr6). Their functional connection is through the shared biological theme of vascular wall integrity and endothelial growth factor signaling.

Another SNX24 variant, rs28891, was specifically associated with coronary artery aneurysm risk in Kawasaki disease. Individuals carrying rs30021-G who also have other variants affecting VWF production (VWF gene variants) or platelet function may have compound effects on hemostasis worth discussing with a hematologist.